We recently published a list of Top 10 Trending Stocks as AI Hype Fades. In this article, we are going to take a look at ...
Charles Schwab Investment Management Inc. lifted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free ...
Zacks Investment Research on MSN7d
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis StudyProtagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated ...
Protagonist Therapeutics (PTGX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in ...
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...
Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
J.P. Morgan analyst Brian Cheng maintained a Buy rating on Protagonist Therapeutics (PTGX – Research Report) yesterday and set a price target ...
We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...
Protagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated icotrokinra (JNJ-2113), an investigational targeted oral peptide that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback